placeholder image

J. Vansteenkiste All authors

About

Publications While At HealthPartners

selected publications

Journal Article
  • Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. 
  • Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. 

    • Contact

    full name

  • J. Vansteenkiste

    • Quick Info

    Publications

    Collaboration